Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more

from BioSpace · host BioSpace

Amylyx shares good news for its investigational GLP-1 blocker; Definium announces positive data for its LSD-based therapy in anxiety; Summit/Akeso’s ivonescimab shows degrading survival benefits; patients treated with Neurocrine’s Prader-Willi drug experience serious adverse events; and Eli Lilly cracks down on the black market for next-gen obesity asset retatrutide.

Episode metadata supplied by the publisher feed · Published Aug 19, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more

0:00 19:08

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of BioSpace?

This episode is 19 minutes long.

When was this BioSpace episode published?

This episode was published on August 19, 2026.

Can I download this BioSpace episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!